Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 11 for:    Achromatopsia

Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia (Colourbridge)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02610582
Recruitment Status : Recruiting
First Posted : November 20, 2015
Last Update Posted : April 1, 2021
Sponsor:
Collaborators:
University Hospital Tuebingen
Ludwig-Maximilians - University of Munich
Information provided by (Responsible Party):
STZ eyetrial

Tracking Information
First Submitted Date  ICMJE September 18, 2015
First Posted Date  ICMJE November 20, 2015
Last Update Posted Date April 1, 2021
Actual Study Start Date  ICMJE November 2015
Estimated Primary Completion Date April 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 29, 2021)
Safety (AE). Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [ Time Frame: Day 0 - Day 365 ]
Safety as the primary endpoint will be assessed by clinical examination of ocular inflammation (slit lamp, fundus biomicroscopy, fundus photography. Systemic safety will be assessed by vital signs, routine clinical chemistry testing (including CRP, ESR) and full/differential blood counts. Immunopathology essays will include specific enzyme-linked immunosorbent assays for humoral antibodies against rAAV8 capsid protein. Biodistribution will be monitored by polymerase chain reaction studies on rAAV8 genome in blood, urine, saliva and tear fluid.
Original Primary Outcome Measures  ICMJE
 (submitted: November 18, 2015)
Safety (AE). Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [ Time Frame: Day 0 - Day 365 ]
Safety as the primary endpoint will be assessed by clinical examination of ocular inflammation (slit lamp, fundus biomicroscopy, angiography, perimetry or electrophysiology). Systemic safety will be assessed by vital signs, routine clinical chemistry testing (including C reactive protein, ESR) and full/differential blood counts. Immunopathology essays will include specific enzyme-linked immunosorbent assays for humoral antibodies against rAAV8 capsid protein and/or CNGA3 gene product and specific enzyme-linked immunosorbent spot assays to monitor cellular immune reactivity against rAAV8 capsid protein and/or CNGA3 gene product. Biodistribution will be monitored by polymerase chain reaction studies on rAAV8 genome in blood, urine, saliva and lachrymal fluid.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 29, 2021)
Efficacy measures. Number of Participants With improved Visual Function. [ Time Frame: Day 14 - Day 365 ]
The investigation of treatment effects as reflected by patient/parent reported outcomes and the efficacy of the intervention on visual function, as well as the evaluation of retinal imaging (safety) are secondary aims of the trial.
Original Secondary Outcome Measures  ICMJE
 (submitted: November 18, 2015)
Efficacy measures. Number of Participants With improved Visual Function. [ Time Frame: Day 14 - Day 365 ]
Efficacy data (improvement in visual function) and patient reported outcomes will be investigated exploratively as well as retinal imaging. They are all secondary endpoints in this trial.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
Official Title  ICMJE Safety and Efficacy of a Bilateral Single Subretinal Injection of rAAV.hCNGA3 in Adult and Minor Patients With CNGA3-linked Achromatopsia Investigated in a Randomized, Wait List Controlled, Observer-masked Trial
Brief Summary The purpose of this study is to proof the safety and efficacy of a single bilateral subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia.
Detailed Description

Title: Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial

Phase: I/II

Indication: CNGA3-linked achromatopsia

Aim: to proof the safety and efficacy of a single bilateral subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia.

Study design: open, mono-center, randomized, wait list controlled, observer-masked trial

Study Population:

Inclusion Criteria (Both Eyes)

  • clinical diagnosis of achromatopsia
  • 6-12 years of age
  • ≥ 18 years of age
  • confirmed mutation in CNGA3
  • BCVA ≥ 20/400
  • a minimal outer nuclear layer thickness of 10µm at 3° eccentricity (normal = 38±6µm)
  • ability to understand and willingness to consent to study protocol
  • no infection with Human Immundeficiency Virus (HIV)
  • Male patients must agree to use condoms during the first 6 months post treatment.
  • Female patients of childbearing potential must agree to use an effective method of birth control during the first 6 months post treatment.
  • negative pregnancy test in women with childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential)

Exclusion Criteria

  • • any other retinopathy due to other diseases e.g. (but not limited to) arterial hypertension, trauma or acquired inflammatory diseases (uveitis serology) , retinopathy of the premature
  • systemic conditions (e.g. coronary heart disease, congenital/genetic conditions, autoimmune disorders) which may affect study participation or outcome measures
  • current or recent participation in other study or administration of biologic agent within the last three months
  • recent (6 months) ocular surgery, intravitreal or subretinal implantation of a medical device
  • known sensitivity to any compound used in the study
  • contraindications to systemic immunosuppression
  • subject/partner of childbearing potential unwilling to use adequate contraception for six months after dosing
  • nursing or pregnant female subject women
  • any other cause that, in the investigator's opinion, renders potential subjects not suitable for the study
  • mutations in another achromatopsia gene
  • contraindications in view of the planned surgery (e.g. anaemia Hb<8g/dl, severe coagulopathy, severe blood pressure fluctuations) including intolerance and contraindications to general anaesthesia
  • ocular opacity and mature cataract
  • ocular infection with herpes simplex virus in medical history
  • history of ocular malignancies
  • disorders of the internal retina (e.g. retinal detachment in the patients history)
  • glaucoma defined as damage of the optic nerve
  • vascular retinal occlusion
  • history of poorly controlled (HbA1c > 7%) Diabetes Mellitus type 1 or type 2
  • patients treated with systemic corticoids within 14 days prior inclusion
  • systemic illness or medically significant abnormal laboratory values >3 UNL in blood analysis including renal and hepatic functions at inclusion
  • absence of vision on the other contralateral eye
  • contraindication to pharmacological mydriasis (e.g. history of angle block glaucoma)

Patient Number: 3 Strata: Cohort A n = 4, ≥ 18 years of age and previous participation in phaseI/II, Cohort B n = 4, ≥ 18 years of age, Cohort C n= 6, 6-12 years of age

Treatment:

Each cohort will receive a single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points. Cohort A, in whom the first eye has received treatment under protocol version 5.0, will only receive one injection in the second eye.

After standard three-port 23G pars plana vitrectomy, balanced salt solution will be used to induce a localized primary retinal detachment in a controlled fashion. Vector solution will be applied using disposable 41G extendible subretinal injection needles within a standard 23G body to fit the port system.

Primary Endpoint:

Primary endpoint safety: Safety assessment 12 months after treatment, descriptively Primary endpoint efficacy: Contrast sensitivity (Pelli Robson 3 m) 6 months after treatment

Key secondary endpoints efficacy 12 months after treatment:

  • Contrast sensitivity (Pelli Robson 3 m)
  • BCVA assessed using the ETDRS visual acuity protocol
  • Microperimetry (MAIA) (20°)
  • Chromatic Pupil Campimetry
  • Patient reported outcomes (VFQ25/CVFQ, A3-PRO) Safety as the primary endpoint will be assessed by clinical examination of ocular inflammation (slit lamp, fundus biomicroscopy, fundus photography. Systemic safety will be assessed by vital signs, routine clinical chemistry testing (including CRP, ESR) and full/differential blood counts. Immunopathology essays will include specific enzyme-linked immunosorbent assays for humoral antibodies against rAAV8 capsid protein. Biodistribution will be monitored by polymerase chain reaction studies on rAAV8 genome in blood, urine, saliva and tear fluid.

Statistical Methods:

Efficacy: The analysis of the primary endpoint (contrast sensitivity after 6 months) will be done using a pre / post comparison for the entire sample including both eyes for cohort B and C (n=10) and only one eye for cohort A (n=4) with GEE correction for the dependency of left and right eye. In the waiting group the second (therapeutic) phase will be used. The dependency appears for cohorts B and C which contribute both eyes but not for cohort A which contributes only one eye to the efficacy analysis. The study is powered for this analysis. We will use the specific type of IEE (Independence Estimating Equations) which reveals correct standard errors and a robust estimate for model parameters.

Additionally, we will compare the Intervention group vs. control group (waiting group) (n=7 vs. 7), using baseline adjusted analysis of covariance and between subject comparisons. This analysis will use GEEs as described for the primary analysis including both eyes of cohort B and C and only the newly treated eye in cohort A. This analysis will be descriptive and provide evidence for the planning of a randomized Phase III trial.

The primary analysis population will be the ITT in which only patients with baseline measurements will be included. For patients providing baseline measurements in one eye, only this eye will be included. Multiple imputation will be done with sampling unit "eye" if only baseline, but not follow up data are available. Descriptive parameters will be given for the full cohort (n=14) and for the sub-strata (n=4, 4, 6 pooled), additionally, correlation analysis descriptively for the comparison of subjective and objective measurements will be done.

Safety (ITT): AEs and SAEs will be documented using line listings and tabulations (MedDRA code will be applied). Frequency tabulations of certain classes of events will be given including two-sided 95% confidence intervals.

The aim of analysis (1) is to gain evidence for a sample size estimation for a phase III trial with similar design, where analysis (2) will be confirmatory and powered according to a sample size estimation.

Time Schedule: of trial November 2015 end of recruitment 04/2022, end of trial 04/2027, duration of trial per patient: one year with four years of follow-up.

The final study report will be prepared after completion of the four year follow-up period (5 years after treatment).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Masking Description:
open label
Primary Purpose: Treatment
Condition  ICMJE Achromatopsia
Intervention  ICMJE Drug: rAAV.hCNGA3
Single subretinal injection of rAAV.hCNGA3
Study Arms  ICMJE
  • Treatment arm
    single subretinal injection of 1x10e11 vector genome particles of rAAV.hCNGA3 in each eye at different time-points
    Intervention: Drug: rAAV.hCNGA3
  • Waiting group Arm
    Waiting group will serve as comparator group first and will receive the treatment at a later timepoint.
    Intervention: Drug: rAAV.hCNGA3
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 29, 2021)
14
Original Estimated Enrollment  ICMJE
 (submitted: November 18, 2015)
9
Estimated Study Completion Date  ICMJE April 2027
Estimated Primary Completion Date April 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria (Both Eyes)

  • clinical diagnosis of achromatopsia
  • 6-12 years of age
  • ≥ 18 years of age
  • confirmed mutation in CNGA3
  • BCVA ≥ 20/400
  • a minimal outer nuclear layer thickness of 10µm at 3° eccentricity (normal = 38±6µm)
  • ability to understand and willingness to consent to study protocol
  • no infection with Human Immundeficiency Virus (HIV)
  • Male patients must agree to use condoms during the first 6 months post treatment.
  • Female patients of childbearing potential must agree to use an effective method of birth control during the first 6 months post treatment.
  • negative pregnancy test in women with childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential)

Exclusion Criteria

  • any other retinopathy due to other diseases e.g. (but not limited to) arterial hypertension, trauma or acquired inflammatory diseases (uveitis serology) , retinopathy of the premature
  • systemic conditions (e.g. coronary heart disease, congenital/genetic conditions, autoimmune disorders) which may affect study participation or outcome measures
  • current or recent participation in other study or administration of biologic agent within the last three months
  • recent (6 months) ocular surgery, intravitreal or subretinal implantation of a medical device
  • known sensitivity to any compound used in the study
  • contraindications to systemic immunosuppression
  • subject/partner of childbearing potential unwilling to use adequate contraception for six months after dosing
  • nursing or pregnant female subject women
  • any other cause that, in the investigator's opinion, renders potential subjects not suitable for the study
  • mutations in another achromatopsia gene
  • contraindications in view of the planned surgery (e.g. anaemia Hb<8g/dl, severe coagulopathy, severe blood pressure fluctuations) including intolerance and contraindications to general anaesthesia
  • ocular opacity and mature cataract
  • ocular infection with herpes simplex virus in medical history
  • history of ocular malignancies
  • disorders of the internal retina (e.g. retinal detachment in the patients history)
  • glaucoma defined as damage of the optic nerve
  • vascular retinal occlusion
  • history of poorly controlled (HbA1c > 7%) Diabetes Mellitus type 1 or type 2
  • patients treated with systemic corticoids within 14 days prior inclusion
  • systemic illness or medically significant abnormal laboratory values >3 UNL in blood analysis including renal and hepatic functions at inclusion
  • absence of vision on the other contralateral eye
  • contraindication to pharmacological mydriasis (e.g. history of angle block glaucoma)
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 6 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Barbara J Wilhelm, Prof. +49 7071 2984898 Barbara.Wilhelm@stz-eyetrial.de
Contact: Dominik Fischer, Prof. +49 7071 298 37 21 dominik.fischer@uni-tuebingen.de
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02610582
Other Study ID Numbers  ICMJE RDC-CNGA3-01
2014-001874-32 ( EudraCT Number )
096/2015 AMG1 ( Other Identifier: Ethics Committee Tübingen )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party STZ eyetrial
Study Sponsor  ICMJE STZ eyetrial
Collaborators  ICMJE
  • University Hospital Tuebingen
  • Ludwig-Maximilians - University of Munich
Investigators  ICMJE
Principal Investigator: Dominik Fischer, Prof. University Hospital Tuebingen, Center for Ophthalmology
PRS Account STZ eyetrial
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP